STAT+: Kennedy, a longtime pharma critic, embraces Trump deal to increase entry to weight problems medication
WASHINGTON — Well being secretary Robert F. Kennedy Jr. was uncharacteristically chummy with pharma executives on the White Home on Thursday as he cheered the Trump administration’s plan for decreasing weight problems remedy costs. Kennedy has railed towards drugmakers prior to now, and his lifestyle-focused Make America Wholesome Once more motion has opposed Medicare protection of GLP-1 weight reduction medication.
However he struck a special tone in commenting on the president’s deal to increase entry to the favored medication made by Eli Lilly and Novo Nordisk, together with for Medicare and Medicaid sufferers, calling it “a momentous accomplishment.”
“This can be a device within the toolkit,” Kennedy stated within the Oval Workplace, with Lilly and Novo’s CEOs standing close by. “It isn’t a silver bullet. It’s an arrow in our quiver.”
